Opportunities
Active Corporate Alliances
OTD is spearheading the following strategic alliances between Harvard and industry partners. These alliances support research in various disciplines in labs across the university, with the goal of developing solutions for global impact. See below and reach out to the OTD Corporate Alliance team with any questions.
Identify and develop therapeutics for medical conditions in oncology, immunology, neurology, and specialty
Harvard University and Ono Pharmaceutical Co., Ltd. (ONO) launched a strategic alliance to advance research across various therapeutic areas. The focus is on the validation of novel therapeutic targets and the discovery of new drugs. Read more.
We are actively soliciting proposals under this alliance.
Launch of Lab1636 to speed the development and translation of biomedical and life-science innovations
Harvard University and Deerfield Management, a health care investment firm, have established a major strategic R&D alliance to launch Lab1636. The focus is to catalyze the development of novel therapeutics and rapidly drive innovations toward clinical validation. Read more.
We are actively soliciting proposals under this alliance.
Therapeutics addressing cardiometabolic diseases and rare blood and endocrine disorders
Harvard University entered into a collaboration with Novo Nordisk and Evotec SE, to establish LAB eN², a translational drug discovery accelerator that aims to nurture preclinical research from academic institutions for the development of novel therapeutics. The focus is on addressing unmet needs in cardiometabolic diseases as well as rare blood and endocrine disorders. Read more.
We are actively soliciting proposals under this alliance.
Addressing emergent viral diseases
Harvard University and AbbVie established a collaborative research alliance, forming a multi-pronged effort at Harvard Medical School to develop novel therapies against emergent viral infections. Read more.
Development of complex medicines
Harvard University and National Resilience, Inc., a manufacturing and technology company, established a R&D alliance directed toward the development of complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Read more.
Let's Talk
Reach out to OTD’s Alliance Management team for more details on active Corporate Alliances at Harvard.
Amazon Web Services
OTD enabled two strategic alliances with Harvard and Amazon Web Services (AWS) to spur advancements in quantum networking and data-driven solutions to complex social problems.
Building a quantum internet
Harvard University and AWS established a research alliance supporting the Harvard Quantum Initiative (HQI) to develop foundational methods and technologies for building a quantum internet. Read more.
Harnessing Data for Social Impact
Through the Harvard Data Science Initiative (HDSI) a second research alliance allows researchers to partner with the AWS Impact Computing Project in applying cloud computing technology to complex challenges such as the climate crisis.
More Details
Reach out to Sam Liss, OTD’s executive director of strategic partnerships, for more details on the AWS alliances.
With industry support, we are developing next-generation, “off-the-shelf” therapeutic approaches that can be applied to a broad range of human diseases. Our goal is to streamline treatment approaches so patients do not have to undergo complicated cell transplantation processes, accelerating treatment and avoiding serious side effects associated with transplantation.